|
Synonyms: CNTO-1959 | Tremfya®
guselkumab is an approved drug (EMA & FDA (2017))
Compound class:
Antibody
Comment: Guselkumab is a monoclonal antibody directed against interleukin-23A (IL23A). It is being investigated as a treatment for plaque psoriasis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| No information available. |
Summary of Clinical Use  |
| Having completed Phase 3 clinical trials for various forms of psoriasis, guselkumab was approved in 2017 for patients with moderate to severe plaque psoriasis. Click here to link to ClinicalTrials.gov's listing of Phase 3 guselkumab trials. |
| Mechanism Of Action and Pharmacodynamic Effects |
| The cytokine IL23 plays an important role in modulating the immune system. Abberant expression of IL23 has been implicated in the pathogenesis of autoimmune diseases such as psoriasis [2] and arthritis [4]. Guselkumab neutralises circulating IL23 by binding the IL23A (p19) subunit, and thereby reduces pathological disease symptoms. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
